Virtual Library

Start Your Search

Junji Ichinose



Author of

  • +

    P1.13 - Radiology/Staging/Screening (ID 699)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Radiology/Staging/Screening
    • Presentations: 1
    • +

      P1.13-005 - Is Tumor Size for the T4 Descriptor in Lung Cancer Staging Appropriate? (ID 8085)

      09:30 - 09:30  |  Presenting Author(s): Junji Ichinose

      • Abstract
      • Slides

      Background:
      According to the 8th Edition of the TNM Classification of Lung Cancer, a tumor of >7 cm in diameter is upstaged to T4 from T3 based on the prognostic analysis of patients with pT1–4N0M0R0. However, there are two major problems with this classification. The first is selection bias; very few patients with non-size-based T4 undergo resection, whereas most patients with large tumors have surgery. The second is a diagnostic problem. Additional tumor nodules in a different ipsilateral lobe (pm2) are also T4 descriptors; however, multiple primary lung cancers may be misdiagnosed as T4 lung cancer with intrapulmonary metastasis.

      Method:
      A total of 378 patients with pT3–4N0–1M0 (according to the new classification) underwent complete or incomplete resection from 1992 to 2011. T4 was subdivided into invT4 (local invasion), multiple-pmT4 (pm2 with multiple nodules), single-pmT4 (single pm2), and sizeT4 (>7 cm).

      Result:
      The number of patients with invT4/multiple-pmT4/single-pmT4/sizeT4/T3 was 13/12/9/61/283; 5-year overall survival (OS) was 23%/25%/67%/46%/64%; and 5-year disease-free survival (DFS) was 15%/17%/67%/39%/55%, respectively. Patients with invT4 and multiple-pmT4 had poorer prognosis than those with sizeT4 in multivariate analysis (OS, hazard ratio = 2.6, p < 0.05; DFS, hazard ratio = 3.2, p < 0.01). Figure 1



      Conclusion:
      The extremely favorable outcome of single-pmT4 suggests the possibility of it being mixed up with multiple primary cancers. Non-size-based T4 patients had poorer prognosis than did sizeT4 patients even in surgical candidates, and the outcome of non-surgically treated patients seemed still worse. Tumors of >7 cm in diameter should not be treated the same as a non-size-based T4 and should be reclassified as T3b.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.05 - Early Stage NSCLC (ID 706)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Early Stage NSCLC
    • Presentations: 1
    • +

      P2.05-016 - Clinical Importance and Application of New T Descriptors in the 8th TNM Classification for Pathological T0-1 Lung Adenocarcinoma (ID 9341)

      09:30 - 09:30  |  Author(s): Junji Ichinose

      • Abstract
      • Slides

      Background:
      In the new TNM classification (8th), significant revision was made for pathological (p) T descriptors. Tumors, 3 cm or less in size, measuring invasive size, were subclassified into five categories, Tis, T1mi, T1a, T1b and T1c, termed T0-1 tumors here. Purpose of this study was to examine clinical importance of new pT descriptors and apply to indication criteria of limited surgery for pT0-1 lung adenocarcinoma.

      Method:
      We retrospectively reviewed pathological data of lung adenocarcinomas surgically resected between 2011 and 2016 at our institute, and reclassified them according to the new TNM classification. We found 874 tumors classified as pT0-1. We compared invasion-related factors such as lymph node (LN) metastasis, lymphatic and /or vascular invasion (LVI) and existence of lepidic component among the five T categories.

      Result:
      There were 154, 196, 195, 255 and 74 cases in the pTis, T1mi, T1a, T1b and T1c category, respectively. LN metastasis was found in 50 of 874 (6%) cases. LN metastasis rates were 0%, 2%, 10% and 27% in T1mi, T1a, T1b and T1c, respectively. In 108 of 874 cases, invasive size was equal to whole tumor size, meaning that they contain less of lepidic component. LN metastasis rates of the 108 cases were 13%, 13% and 27% in T1a, T1b and T1c, respectively, implying that LN metastasis of T1a diseases were much often with less lepidic component. In the 824 cases without LN metastases, LVI was observed in 156 (19%) cases. LVI rates were 1%, 21%, 39 and 46% in T1mi, T1a, T1b and T1c, respectively. In 89 of 824 cases, invasive size was equal to whole tumor size. LVI rates of the 89 cases were 31%, 54% and 54% in T1a, T1b and T1c, respectively, meaning that LVI rates were more frequent in T1a-c diseases with less lepidic component.

      Conclusion:
      LN metastasis was rare (2%) in T1a diseases, and they may be good candidates for limited surgery such as segmentectomy. However, T1a diseases with less lepidic component, showing 13% of LN metastasis, may be difficult to cure by limited surgery. On the other hand, in T1b and T1c diseases, LN metastasis rates did not significantly differ between cases with and without lepidic component. T1mi diseases, rarely showing LVI, can be managed same as Tis and cured by partial resection. Taken together, it is the most important to predict pathological T descriptors preoperatively accurately by imaging analysis for T0-1 lung adenocarcinoma.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.